Comment
doi: 10.1093/annonc/mdx254.
Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest
Affiliations
- PMID: 28911081
- DOI: 10.1093/annonc/mdx254
Item in Clipboard
Comment
Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest
Ann Oncol.
.
Free article
No abstract available
Comment in
-
Response to 'Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest'.Ann Oncol. 2017 Dec 1;28(12):3101-3103. doi: 10.1093/annonc/mdx533. Ann Oncol. 2017. PMID: 29045508 No abstract available.
Comment on
-
Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial.Ann Oncol. 2017 Apr 1;28(4):777-783. doi: 10.1093/annonc/mdx009. Ann Oncol. 2017. PMID: 28137739 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
